| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd | 25% | $13,950,000 | 13,950,000 | Panacea Innovation Limited | 21 Jul 2025 | |||
| Wei Zheng | 9.9% | $8,347,120 | 5,527,528 | Wei Zheng | 26 Nov 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 1,582 shares of Connect Biopharma Holdings Ltd - Ordinary Shares, par value $0.000174 (CNTB). This represents 0% of the company’s total 55,833,616 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 1,582 | $2,389 | -$2,397,515 | $1.51 | 1 |
| 2025 Q2 | 2,444,820 | $2,399,065 | -$179,460 | $0.98 | 17 |
| 2025 Q1 | 2,827,742 | $1,555,037 | -$242,900 | $0.55 | 13 |
| 2024 Q4 | 3,181,027 | $4,372,490 | +$306,229 | $1.38 | 14 |
| 2024 Q3 | 2,944,726 | $4,229,340 | +$101,251 | $1.44 | 11 |
| 2024 Q2 | 2,976,236 | $4,523,173 | -$1,478,482 | $1.52 | 12 |
| 2024 Q1 | 3,947,159 | $6,867,831 | -$3,787,306 | $1.74 | 11 |
| 2023 Q4 | 7,118,656 | $8,400,371 | -$3,060,514 | $1.18 | 14 |
| 2023 Q3 | 10,078,543 | $8,221,166 | -$60,098 | $0.80 | 12 |
| 2023 Q2 | 10,358,458 | $11,684,999 | -$631,607 | $1.11 | 15 |
| 2023 Q1 | 10,919,115 | $10,918,005 | -$44,044 | $1.00 | 15 |
| 2022 Q4 | 11,067,830 | $9,603,876 | +$2,501 | $0.87 | 18 |
| 2022 Q3 | 217,709 | $282,000 | -$1,721,326 | $1.67 | 5 |
| 2022 Q2 | 14,969,473 | $13,034,000 | -$10,410,998 | $0.87 | 26 |
| 2022 Q1 | 17,687,819 | $53,391,000 | -$622,344 | $3.02 | 26 |
| 2021 Q4 | 16,966,777 | $87,370,000 | -$80,695,326 | $5.15 | 28 |
| 2021 Q3 | 19,395,645 | $467,497,000 | +$8,028,087 | $24.20 | 20 |
| 2021 Q2 | 19,072,268 | $372,436,000 | +$73,098,989 | $19.53 | 16 |
| 2021 Q1 | 15,391,128 | $284,643,000 | +$284,643,000 | $18.50 | 26 |